Gilead Secures Regulatory Approval for Arcellx Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 17 2026
0mins
Should l Buy GILD?
Source: Newsfilter
- Acquisition Approval: Gilead announced it has obtained all necessary regulatory approvals for the acquisition of Arcellx, marking a significant milestone that is expected to enhance Gilead's market position in the biopharmaceutical sector.
- Tender Offer Extension: Gilead has extended the expiration date of its tender offer for Arcellx to April 27, 2026, ensuring that the transaction can be completed smoothly upon satisfying all closing conditions, thereby strengthening its foothold in oncology.
- Shareholder Response: As of April 16, 2026, approximately 10,271,823 shares of Arcellx have been validly tendered, representing about 17.5% of the outstanding shares, indicating positive shareholder response that may support subsequent integration efforts.
- Future Outlook: Gilead aims to achieve over $6 billion in global sales of Arcellx's product by 2030, which, if realized, will trigger a $5 cash payment for holders of the contractual contingent value rights, further boosting investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 132.060
Low
105.00
Averages
137.88
High
154.00
Current: 132.060
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada for PrEP, and others. It also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. It has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. It operates in over 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development
- Significant Partnership: Bristol Myers Squibb has announced a potential multi-billion dollar partnership with Hengrui Pharma, aiming to co-develop around a dozen drugs, including four that Bristol will send to China for early-stage clinical trials, marking a new phase of international collaboration in drug development.
- Shift in R&D Model: This collaboration represents a departure from traditional licensing agreements, as both companies will contribute resources to drug development, positioning China as a vital part of the global pharmaceutical R&D ecosystem and highlighting U.S. drugmakers' increasing focus on the Chinese market.
- Market Trend Shift: According to DealForma, over half of large pharmaceutical licensing deals this year have originated from China, up from 39% last year, indicating a growing trend among U.S. and European biopharmaceutical companies to shift early drug development to China to expedite market entry.
- Future Industry Outlook: Experts predict that early-stage drug discovery will increasingly move to China due to its ability to conduct studies at lower costs and faster timelines, potentially reshaping the U.S. pharmaceutical landscape and encouraging more companies to initiate early clinical trials in China.
See More
Gilead Sciences Prices $3 Billion Senior Notes Offering
- Bond Offering Size: Gilead Sciences announced a public offering of senior unsecured notes totaling $3 billion, which includes $500 million of 4.250% notes maturing in 2028, $1 billion of 4.400% notes maturing in 2029, $1 billion of 4.600% notes maturing in 2031, and $500 million of 4.900% notes maturing in 2034, demonstrating the company's strong capital market financing capabilities.
- Use of Proceeds: The funds raised from this bond issuance will be allocated for general corporate purposes, including acquisitions, investments, strategic transactions, or other business opportunities, indicating Gilead's proactive strategy to expand its business and enhance market competitiveness.
- Issuance Timeline: The bond offering is expected to close on May 20, 2026, pending standard conditions, providing investors with a clear expectation of cash inflow and helping to boost market confidence.
- Market Reaction Outlook: Gilead's bond issuance is likely to attract investor interest in the current market environment, particularly against the backdrop of the biopharmaceutical industry seeking funding support, which is expected to positively impact the company's financial position.
See More
Gilead Sciences Prices $3 Billion Senior Unsecured Notes Offering
- Bond Offering Size: Gilead Sciences announced the pricing of $3 billion in senior unsecured notes, which includes $500 million of 4.250% notes maturing in 2028, $1 billion of 4.400% notes maturing in 2029, $1 billion of 4.600% notes maturing in 2031, and $500 million of 4.900% notes maturing in 2034, reflecting the company's robust capital market financing capabilities.
- Clear Use of Proceeds: The net proceeds from this bond offering will be used for general corporate purposes, including potential acquisitions, investments, and other strategic transactions, indicating Gilead's proactive approach to expanding its business and seizing new opportunities.
- Strong Underwriter Lineup: Barclays Capital, BofA Securities, and Citigroup Global Markets are acting as lead underwriters for this offering, enhancing market confidence in the bonds while providing strong market support for the company.
- Compliance and Transparency: The offering complies with SEC registration requirements, with all related documents available for free on the SEC's website, ensuring that investors can fully understand the investment risks and related information, demonstrating the company's commitment to compliance and transparency.
See More
Gilead Presents New Data at EASL Congress on Livdelzi and Bulevirtide
- Livdelzi Clinical Data: Gilead presented randomized and long-term study data for Livdelzi (seladelpar) in primary biliary cholangitis (PBC) patients at EASL, demonstrating its efficacy in reducing ALP levels, which may enhance patient quality of life and has significant clinical implications.
- HDV Research Progress: Gilead showcased clinical data on bulevirtide for HDV co-infection in chronic hepatitis B patients, emphasizing its safety and tolerability across diverse HDV patient populations, reflecting the company's ongoing leadership in HDV treatment.
- HCV Elimination Efforts: The company also highlighted progress in hepatitis C elimination research, particularly a 7-year outcome study in prisons, indicating its positive contributions to public health and potential influence on future policy-making.
- Future Research Directions: Gilead's studies include a machine learning model to identify risk factors for liver disease progression in HDV-infected patients, showcasing the company's innovative potential in leveraging new technologies for liver disease management.
See More
Fluence Energy Shares Soar Nearly 30% After Upgrades
- Fluence Energy Surge: Fluence Energy's stock soared nearly 30% after its fiscal second-quarter EBITDA exceeded Wall Street estimates, following a prior session surge of about 40%, indicating strong market confidence in its growth potential and attracting more investor interest.
- Corpay Raises Guidance: Corpay shares jumped 10% after the company raised its full-year earnings guidance to a range of $26.30 to $27.10 per share, surpassing analyst expectations of $26.05, reflecting robust performance in the corporate payments sector and potentially increasing market share.
- Akamai Technologies Rises: Akamai's stock surged 20% after securing an $1.8 billion commitment from a leading U.S. frontier model provider for its Cloud Infrastructure Services, indicating strong demand in the market, while also reporting a first-quarter adjusted earnings beat that bolstered investor confidence.
- Upwork Restructuring Impact: Upwork's shares tumbled 21% following its announcement of a 24% workforce reduction to ensure profitability, despite slightly lower-than-expected first-quarter earnings and revenue, which may affect its future competitive position and investor sentiment.
See More
Gilead Sciences Posts Strong Q1 2026 Performance Driven by HIV Drug Growth
- Revenue Growth: Gilead Sciences reported a 4% year-on-year increase in total revenue for Q1 2026, reaching $7 billion, exceeding analyst expectations and demonstrating strong performance in the HIV drug sector.
- HIV Drug Sales: Of the $6.9 billion in total product sales, the HIV portfolio contributed $5 billion, growing 10% year-on-year, with Biktarvy generating $3.36 billion, up from $3.15 billion in 2025, solidifying its market leadership.
- PrEP Drug Performance: Sales of Descovy reached $807 million, a 38% increase from 2025, surpassing market expectations, while the newly launched Yeztugo achieved early success with $166 million in sales this quarter, projected to become a blockbuster product.
- New Drug Development Outlook: Gilead's anitocabtagene autoleucel (anito-cel) is under FDA review, expected to generate revenue in early 2027, with analysts believing it could be a strong contender in treating multiple myeloma, potentially reshaping the market landscape.
See More
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development
- Significant Partnership: Bristol Myers Squibb has announced a potential multi-billion dollar partnership with Hengrui Pharma, aiming to co-develop around a dozen drugs, including four that Bristol will send to China for early-stage clinical trials, marking a new phase of international collaboration in drug development.
- Shift in R&D Model: This collaboration represents a departure from traditional licensing agreements, as both companies will contribute resources to drug development, positioning China as a vital part of the global pharmaceutical R&D ecosystem and highlighting U.S. drugmakers' increasing focus on the Chinese market.
- Market Trend Shift: According to DealForma, over half of large pharmaceutical licensing deals this year have originated from China, up from 39% last year, indicating a growing trend among U.S. and European biopharmaceutical companies to shift early drug development to China to expedite market entry.
- Future Industry Outlook: Experts predict that early-stage drug discovery will increasingly move to China due to its ability to conduct studies at lower costs and faster timelines, potentially reshaping the U.S. pharmaceutical landscape and encouraging more companies to initiate early clinical trials in China.
See More
Gilead Sciences Prices $3 Billion Senior Notes Offering
- Bond Offering Size: Gilead Sciences announced a public offering of senior unsecured notes totaling $3 billion, which includes $500 million of 4.250% notes maturing in 2028, $1 billion of 4.400% notes maturing in 2029, $1 billion of 4.600% notes maturing in 2031, and $500 million of 4.900% notes maturing in 2034, demonstrating the company's strong capital market financing capabilities.
- Use of Proceeds: The funds raised from this bond issuance will be allocated for general corporate purposes, including acquisitions, investments, strategic transactions, or other business opportunities, indicating Gilead's proactive strategy to expand its business and enhance market competitiveness.
- Issuance Timeline: The bond offering is expected to close on May 20, 2026, pending standard conditions, providing investors with a clear expectation of cash inflow and helping to boost market confidence.
- Market Reaction Outlook: Gilead's bond issuance is likely to attract investor interest in the current market environment, particularly against the backdrop of the biopharmaceutical industry seeking funding support, which is expected to positively impact the company's financial position.
See More
Gilead Sciences Prices $3 Billion Senior Unsecured Notes Offering
- Bond Offering Size: Gilead Sciences announced the pricing of $3 billion in senior unsecured notes, which includes $500 million of 4.250% notes maturing in 2028, $1 billion of 4.400% notes maturing in 2029, $1 billion of 4.600% notes maturing in 2031, and $500 million of 4.900% notes maturing in 2034, reflecting the company's robust capital market financing capabilities.
- Clear Use of Proceeds: The net proceeds from this bond offering will be used for general corporate purposes, including potential acquisitions, investments, and other strategic transactions, indicating Gilead's proactive approach to expanding its business and seizing new opportunities.
- Strong Underwriter Lineup: Barclays Capital, BofA Securities, and Citigroup Global Markets are acting as lead underwriters for this offering, enhancing market confidence in the bonds while providing strong market support for the company.
- Compliance and Transparency: The offering complies with SEC registration requirements, with all related documents available for free on the SEC's website, ensuring that investors can fully understand the investment risks and related information, demonstrating the company's commitment to compliance and transparency.
See More
Gilead Presents New Data at EASL Congress on Livdelzi and Bulevirtide
- Livdelzi Clinical Data: Gilead presented randomized and long-term study data for Livdelzi (seladelpar) in primary biliary cholangitis (PBC) patients at EASL, demonstrating its efficacy in reducing ALP levels, which may enhance patient quality of life and has significant clinical implications.
- HDV Research Progress: Gilead showcased clinical data on bulevirtide for HDV co-infection in chronic hepatitis B patients, emphasizing its safety and tolerability across diverse HDV patient populations, reflecting the company's ongoing leadership in HDV treatment.
- HCV Elimination Efforts: The company also highlighted progress in hepatitis C elimination research, particularly a 7-year outcome study in prisons, indicating its positive contributions to public health and potential influence on future policy-making.
- Future Research Directions: Gilead's studies include a machine learning model to identify risk factors for liver disease progression in HDV-infected patients, showcasing the company's innovative potential in leveraging new technologies for liver disease management.
See More
Fluence Energy Shares Soar Nearly 30% After Upgrades
- Fluence Energy Surge: Fluence Energy's stock soared nearly 30% after its fiscal second-quarter EBITDA exceeded Wall Street estimates, following a prior session surge of about 40%, indicating strong market confidence in its growth potential and attracting more investor interest.
- Corpay Raises Guidance: Corpay shares jumped 10% after the company raised its full-year earnings guidance to a range of $26.30 to $27.10 per share, surpassing analyst expectations of $26.05, reflecting robust performance in the corporate payments sector and potentially increasing market share.
- Akamai Technologies Rises: Akamai's stock surged 20% after securing an $1.8 billion commitment from a leading U.S. frontier model provider for its Cloud Infrastructure Services, indicating strong demand in the market, while also reporting a first-quarter adjusted earnings beat that bolstered investor confidence.
- Upwork Restructuring Impact: Upwork's shares tumbled 21% following its announcement of a 24% workforce reduction to ensure profitability, despite slightly lower-than-expected first-quarter earnings and revenue, which may affect its future competitive position and investor sentiment.
See More
Gilead Sciences Posts Strong Q1 2026 Performance Driven by HIV Drug Growth
- Revenue Growth: Gilead Sciences reported a 4% year-on-year increase in total revenue for Q1 2026, reaching $7 billion, exceeding analyst expectations and demonstrating strong performance in the HIV drug sector.
- HIV Drug Sales: Of the $6.9 billion in total product sales, the HIV portfolio contributed $5 billion, growing 10% year-on-year, with Biktarvy generating $3.36 billion, up from $3.15 billion in 2025, solidifying its market leadership.
- PrEP Drug Performance: Sales of Descovy reached $807 million, a 38% increase from 2025, surpassing market expectations, while the newly launched Yeztugo achieved early success with $166 million in sales this quarter, projected to become a blockbuster product.
- New Drug Development Outlook: Gilead's anitocabtagene autoleucel (anito-cel) is under FDA review, expected to generate revenue in early 2027, with analysts believing it could be a strong contender in treating multiple myeloma, potentially reshaping the market landscape.
See More
